Clinical Trials
47 trialsOxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer
National Cancer Institute (NCI)
KANDLELIT-012
Merck Sharp & Dohme LLC
OPTICAL
Sun Yat-sen University
Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery
Alliance for Clinical Trials in Oncology
Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
National Cancer Institute (NCI)
Neoadjuvant Chemotherapy Versus Standard Treatment in Patients With Locally Advanced Colon Cancer
Vejle Hospital
IROCAS
UNICANCER
The Sagittarius Trial
IFOM ETS - The AIRC Institute of Molecular Oncology
Neoadjuvant CAPOX Plus Tislelizumab vs CAPOX in MSS High-Risk Locally Advanced Colon Cancer
First Affiliated Hospital of Guangxi Medical University
A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer
Pfizer
Pre-Operative Treatment in REseCTable COlon CanceR
Charite University, Berlin, Germany
Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer
Alliance for Clinical Trials in Oncology
iMAGINE
Medical University of Vienna
IDEA
GERCOR - Multidisciplinary Oncology Cooperative Group
PROMENADE
University of Roma La Sapienza
Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity in Patients With Colon Cancer or Rectal Cancer Receiving Oxaliplatin-Based Combination Chemotherapy
Alliance for Clinical Trials in Oncology
Leucovorin and Fluorouracil With or Without Oxaliplatin Compared to Capecitabine With or Without Oxaliplatin in Treating Patients With Metastatic Colorectal Cancer
Medical Research Council
Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer
National Cancer Institute (NCI)
Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer
Alliance for Clinical Trials in Oncology
Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer
Alliance for Clinical Trials in Oncology
Fluorouracil, Leucovorin, and Oxaliplatin With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II or Stage III Colon Cancer
National Cancer Institute (NCI)
Study Investigating the Role of Oxaliplatin Duration in Modified FOLFOX-6 or CAPOX Regimen as Adjuvant Colon Cancer Therapy
Samsung Medical Center
Combination Chemotherapy After Surgery in Treating Patients With High-Risk Stage II or Stage III Colorectal Cancer
Cancer Research UK, Glasgow
FOLFIRI or FOLFOX With or Without Cetuximab in Patients With Metastatic Adenocarcinoma of the Colon or Rectum
Alliance for Clinical Trials in Oncology
Combination Chemotherapy Plus Bevacizumab With or Without Oxaliplatin in Treating Older Patients With Metastatic Colorectal Cancer
Alliance for Clinical Trials in Oncology
Systemic Chemotherapy With or Without Intraperitoneal Chemohyperthermia in Treating Patients Undergoing Surgery for Peritoneal Carcinomatosis From Colorectal Cancer
UNICANCER
TRIBE
Gruppo Oncologico del Nord-Ovest
BEBYP
Gruppo Oncologico del Nord-Ovest
TOSCA
Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente
Comparison of Three Chemotherapy Regimens in Treating Patients With Metastatic Colorectal Cancer
National Cancer Institute (NCI)
Combination Chemotherapy in Treating Patients With Unresectable Metastatic Colorectal Cancer
National Cancer Institute (NCI)
Irinotecan With or Without Oxaliplatin in Treating Patients With Metastatic Colorectal Cancer
National Cancer Institute (NCI)
Oxaliplatin and Bevacizumab (Avastinâ„¢) With Either Fluorouracil and Leucovorin or Capecitabine in Treating Patients With Advanced Colorectal Cancer
National Cancer Institute (NCI)
Combination Chemotherapy With or Without Cetuximab as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer
National Cancer Institute (NCI)
Combination Chemotherapy With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for High Risk Stage II or Stage III Colon Cancer
Hoffmann-La Roche
Oxaliplatin and Capecitabine With or Without an Hepatic Arterial Infusion With Floxuridine in Treating Patients Who Are Undergoing Surgery and/or Ablation for Liver Metastases Due to Colorectal Cancer
NSABP Foundation Inc
Irinotecan Compared With Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer
National Cancer Institute (NCI)
Combination Chemotherapy and Bevacizumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Colorectal Cancer
National Cancer Institute (NCI)
Combination Chemotherapy With or Without Bevacizumab Compared With Bevacizumab Alone in Treating Patients With Advanced or Metastatic Colorectal Cancer That Has Been Previously Treated
National Cancer Institute (NCI)
Combination Chemotherapy With or Without Cetuximab Before and After Surgery in Treating Patients With Resectable Liver Metastases Caused By Colorectal Cancer
University of Southampton
Fluorouracil Plus Leucovorin With or Without Oxaliplatin in Treating Patients With Stage II or Stage III Colon Cancer
National Cancer Institute (NCI)
Combination Chemotherapy in Treating Patients With Recurrent or Metastatic Colorectal Cancer
European Organisation for Research and Treatment of Cancer - EORTC
MIROX
GERCOR - Multidisciplinary Oncology Cooperative Group
Surgery With or Without Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer
National Cancer Institute (NCI)
MOSAIC - Multicenter International Study of Oxaliplatin/ 5FU-LV in the Adjuvant Treatment of Colon Cancer
Sanofi
Combination Chemotherapy in Treating Patients With Recurrent Metastatic Colorectal Cancer
National Cancer Institute (NCI)
Comparing Two Combination Chemotherapy Regimens in Treating Patients With Metastatic Colorectal Cancer
National Cancer Institute (NCI)